Serology Testing, also known as antibody testing, plays a crucial role in vaccine development, monitoring vaccine effectiveness, and assessing population immunity. This diagnostic technique involves detecting and measuring the levels of antibodies in a person's blood, which can indicate past or current infection with a specific pathogen or exposure to a vaccine. In the context of vaccines, serology testing is used to evaluate the immune response elicited by vaccination. After receiving a vaccine, the body typically produces antibodies specific to the antigens contained in the vaccine. Serology testing allows healthcare providers and researchers to assess whether an individual has developed a sufficient antibody response to the vaccine and determine their level of immunity against the target disease.
Serology testing is particularly useful for monitoring the effectiveness of vaccines over time and identifying populations that may require booster doses to maintain immunity. For example, serological studies have been used to assess the duration of immunity following vaccination against diseases such as measles, mumps, rubella, and hepatitis B. In addition to evaluating vaccine responses, serology testing can also be used to assess population immunity and monitor disease outbreaks. By testing samples from a representative sample of the population, public health authorities can estimate the proportion of individuals who have been infected with a particular pathogen or vaccinated against it, providing valuable insights into the overall level of immunity within the community.
Serology testing has played a crucial role in the global response to the COVID-19 pandemic. Antibody tests have been developed to detect antibodies specific to SARS-CoV-2, the virus that causes COVID-19, allowing healthcare providers to identify individuals who have been previously infected with the virus and potentially developed immunity. Serological surveys have also been conducted to assess the prevalence of COVID-19 infection in different populations and inform public health decision-making.
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : Capillary electrophoresis for adjuvanted multivalent recombinant vaccine purity determination
Ashley Prout, Merck, United States
Title : Hypersensitivity and anti-SARS-COV-2 vaccination: A retrospective study of the year 2021 at the University Hospital Center of Tours (France)
Faure Quentin, The Savoie Metropolitan Hospital Center, France
Title : Targeting resistance: New 4-substituted pyrazolidine and isoxazolidine as antibiotics with interesting antimicrobial activities
Yousfi Tarek, Nationale Research for Biotechnology Research Center, Algeria